Flputnam Investment Management Co. Raises Stock Position in Bristol Myers Squibb Company $BMY

Key Points

• Flputnam Investment Management increased its Bristol Myers Squibb position by 12.6% in the second quarter, adding 26,360 shares for a total holding of 236,011 shares valued at approximately $13.6 million. Institutional investors collectively own 76.41% of the company.
• Bristol Myers Squibb reported quarterly EPS of $2.04, beating estimates of $1.60, while revenue reached $12.97 billion and rose 5.7% year over year. The company reaffirmed fiscal 2026 EPS guidance of $6.75–$7.00.
• The company pays a quarterly dividend of $0.63, equivalent to an annualized $2.52 dividend and a 3.9% yield. Analysts maintain a “Moderate Buy” consensus rating with an average price target of $66.06.

Flputnam Investment Management Co. grew its holdings in shares of Bristol Myers Squibb Company (NYSE:BMY - Free Report) by 12.6% in the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 236,011 shares of the biopharmaceutical company's stock after acquiring an additional 26,360 shares during the period. Flputnam Investment Management Co.'s holdings in Bristol Myers Squibb were worth $13,599,000 as of its most recent SEC filing.

Other large investors have also modified their holdings of the company. Swiss RE Ltd. acquired a new stake in Bristol Myers Squibb in the fourth quarter worth about $25,000. Darwin Wealth Management LLC purchased a new position in shares of Bristol Myers Squibb in the 2nd quarter valued at approximately $25,000. Physician Wealth Advisors Inc. boosted its stake in Bristol Myers Squibb by 73.5% in the 4th quarter. Physician Wealth Advisors Inc. now owns 477 shares of the biopharmaceutical company's stock worth $26,000 after purchasing an additional 202 shares in the last quarter. Bayban acquired a new stake in Bristol Myers Squibb in the 4th quarter worth approximately $31,000. Finally, EQ Wealth Advisors LLC purchased a new stake in Bristol Myers Squibb during the 4th quarter worth approximately $32,000. Institutional investors own 76.41% of the company's stock.

Bristol Myers Squibb Stock Up 1.4%

Bristol Myers Squibb stock opened at $64.71 on Tuesday. The business's 50-day moving average price is $59.75 and its 200 day moving average price is $59.06. The company has a quick ratio of 1.38, a current ratio of 1.53 and a debt-to-equity ratio of 1.89. The firm has a market cap of $132.18 billion, a price-to-earnings ratio of 14.25, a price-to-earnings-growth ratio of 0.17 and a beta of 0.22. Bristol Myers Squibb Company has a 52 week low of $42.52 and a 52 week high of $68.10.

Bristol Myers Squibb (NYSE:BMY - Get Free Report) last announced its quarterly earnings results on Thursday, July 30th. The biopharmaceutical company reported $2.04 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.60 by $0.44. The company had revenue of $12.97 billion during the quarter, compared to the consensus estimate of $11.74 billion. Bristol Myers Squibb had a return on equity of 66.90% and a net margin of 18.87%.Bristol Myers Squibb's revenue for the quarter was up 5.7% on a year-over-year basis. During the same period in the previous year, the company posted $1.46 earnings per share. Bristol Myers Squibb has set its FY 2026 guidance at 6.750-7.000 EPS. As a group, sell-side analysts anticipate that Bristol Myers Squibb Company will post 6.95 earnings per share for the current year.

Bristol Myers Squibb Announces Dividend

The company also recently disclosed a quarterly dividend, which was paid on Monday, August 3rd. Shareholders of record on Thursday, July 2nd were given a $0.63 dividend. The ex-dividend date was Thursday, July 2nd. This represents a $2.52 dividend on an annualized basis and a dividend yield of 3.9%. Bristol Myers Squibb's dividend payout ratio is 55.51%.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently commented on BMY shares. Piper Sandler initiated coverage on shares of Bristol Myers Squibb in a research note on Wednesday, August 5th. They set an "overweight" rating for the company. TD Cowen started coverage on Bristol Myers Squibb in a research report on Wednesday, August 5th. They set a "buy" rating for the company. BMO Capital Markets reiterated a "market perform" rating on shares of Bristol Myers Squibb in a research note on Monday, July 27th. Cantor Fitzgerald reissued a "neutral" rating and issued a $59.00 price objective (up from $54.00) on shares of Bristol Myers Squibb in a report on Friday, July 31st. Finally, Roth Capital started coverage on Bristol Myers Squibb in a report on Wednesday, August 5th. They set a "buy" rating and a $75.00 target price for the company. One investment analyst has rated the stock with a Strong Buy rating, twelve have assigned a Buy rating, eleven have assigned a Hold rating and one has assigned a Sell rating to the company's stock. According to data from MarketBeat.com, Bristol Myers Squibb currently has an average rating of "Moderate Buy" and an average price target of $66.06.

Bristol Myers Squibb Company Profile

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company's core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS's marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source